MARKET

LXRX

LXRX

Lexicon PHARM
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.870
+0.030
+0.62%
After Hours: 4.870 0 0.00% 16:00 06/11 EDT
OPEN
4.820
PREV CLOSE
4.840
HIGH
4.920
LOW
4.720
VOLUME
403.99K
TURNOVER
--
52 WEEK HIGH
9.65
52 WEEK LOW
1.030
MARKET CAP
703.17M
P/E (TTM)
-36.5067
1D
5D
1M
3M
1Y
5Y
Lexicon Pharmaceuticals to Participate in the 2021 Jefferies Virtual Healthcare Conference
THE WOODLANDS, Texas, May 26, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, Lexicon’s president and chief executive officer, will present at the 2021 Jefferies Virtual Healthcare Conference on Wedn...
GlobeNewswire · 05/26 20:15
Lexicon Pharmaceuticals Announces Two Presentations at the American College of Cardiology’s 70th Annual Scientific Session
THE WOODLANDS, Texas, May 13, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today there will be two virtual presentations highlighting sotagliflozin during the American College of Cardiology’s 70th Annual Scientific Sessi...
GlobeNewswire · 05/13 20:15
Global Cancer Cachexia Pipeline Insights Market Report 2020 Featuring AEterna Zentaris, Smartfish AS, Tetra Bio-Pharma, Pfizer, Helsinn Healthcare SA, & Lexicon Pharmaceuticals - ResearchAndMarkets.com
The "Cancer Cachexia - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
BusinessWire · 05/13 12:32
Global Anthraquinone Market Growth Share 2021: with Evolving Technologies, Market Dynamics and Forthcoming Developments, Regional Revenue Analysis by Size, Business Advancements till 2027
May 12, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." Global “Anthraquinone Market” Report...
The Express Wire · 05/12 08:56
--Wedbush Cuts Lexicon Pharmaceuticals' PT to $5 From $8 on Adjusted Timelines for Sotaglifozin/Heart Failure, Xermelo/BTC; Neutral Rating Kept
MT Newswires · 05/11 06:42
Lexicon Pharmaceuticals (LXRX) Gets a Hold Rating from Wedbush
Wedbush analyst Liana Moussatos maintained a Hold rating on Lexicon Pharmaceuticals (LXRX) yesterday and set a price target of $5.00. The company's shares
SmarterAnalyst · 05/11 01:35
Irritable Bowel Syndrome Treatment Market 2021: Global Companies by Size, Growth of Manufacturers, Research Findings, and Regional Opportunities Forecast to 2023
May 10, 2021 (The Expresswire) -- The “Irritable Bowel Syndrome Treatment Market” research report is an exclusive research that provides holistic overview of...
The Express Wire · 05/10 12:07
Analysts Offer Insights on Healthcare Companies: Lexicon Pharmaceuticals (LXRX), Zogenix (ZGNX) and Dicerna Pharma (DRNA)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Lexicon Pharmaceuticals (LXRX), Zogenix (ZGNX) and
SmarterAnalyst · 05/07 11:15
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of LXRX. Analyze the recent business situations of Lexicon PHARM through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average LXRX stock price target is 9.00 with a high estimate of 13.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 180
Institutional Holdings: 122.49M
% Owned: 84.83%
Shares Outstanding: 144.39M
TypeInstitutionsShares
Increased
29
5.39M
New
29
3.25M
Decreased
28
7.58M
Sold Out
26
1.80M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.29%
Pharmaceuticals & Medical Research
-0.72%
Key Executives
Chairman/Independent Director
Raymond Debbane
President/Chief Executive Officer/Director
Lonnel Coats
Chief Financial Officer/Executive Vice President
Jeffrey Wade
Executive Vice President
Alan Main
Vice President - Finance
James Tessmer
Vice President/General Counsel
Brian Crum
Independent Director
Philippe Amouyal
Independent Director
Samuel Barker
Independent Director
Robert Lefkowitz
Independent Director
Alan Nies
Independent Director
Frank Palantoni
Independent Director
Christopher Sobecki
Independent Director
Judith Swain
No Data
About LXRX
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of treatments for human disease. The Company's drug programs include Sotagliflozin and LX9211. The Company also has a number of additional compounds into various stages of clinical and preclinical development. The Company’s LX9211 is an orally-delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company intends to initiate a Phase IIa clinical trial evaluating the safety and tolerability of LX9211 and its effects on diabetic peripheral neuropathic (DPN) pain. Its Sotagliflozin is an orally-delivered small molecule compound that is being developed for the treatment of type I diabetes and type II diabetes, heart failure and chronic kidney disease.

Webull offers kinds of Lexicon Pharmaceuticals, Inc. stock information, including NASDAQ:LXRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LXRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LXRX stock methods without spending real money on the virtual paper trading platform.